Deep learning approach identified a gene signature predictive of the severity of renal damage caused by chronic cadmium accumulation.

Journal: Journal of hazardous materials
PMID:

Abstract

Epidemiology studies have indicated that environmental cadmium exposure, even at low levels, will result in chronic cadmium accumulation in the kidney with profound adverse consequences and that the diabetic population is more susceptible. However, the underlying mechanisms are yet not fully understood. In the present study, we applied an animal model to study chronic cadmium exposure-induced renal injury and performed whole transcriptome profiling studies. Repetitive CdCl exposure resulted in cadmium accumulation and remarkable renal injuries in the animals. The diabetic ob/ob mice manifested increased severity of renal injury compared with the wild type C57BL/6 J littermate controls. RNA-Seq data showed that cadmium treatment induced dramatic gene expression changes in a dose-dependent manner. Among the differentially expressed genes include the apoptosis hallmark genes which significantly demarcated the treatment effects. Pathway enrichment and network analyses revealed biological oxidation (mainly glucuronidation) as one of the major stress responses induced by cadmium treatment. We next implemented a deep learning algorithm in conjunction with cloud computing and discovered a gene signature that can predict the degree of renal injury induced by cadmium treatment. The present study provided, for the first time, a comprehensive mechanistic understanding of chronic cadmium-induced nephrotoxicity in normal and diabetic populations at the whole genome level.

Authors

  • Xuefang Feng
    Department of Nephrology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, China.
  • Xian Jin
    Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
  • Rong Zhou
  • Qian Jiang
    College of Engineering, South China Agricultural University, Guangzhou 510642, China.
  • Yanan Wang
    Vasculocardiology Department, The Third People's Hospital of Datong, Datong, Shanxi, China.
  • Xing Zhang
    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Ke Shang
    EnnovaBio Pharmaceuticals, Shanghai 201203, China; Ennovabio (ZheJiang) Pharmaceuticals, Shaoxing, Zhejiang 312366, China.
  • Jianhua Zhang
  • Chen Yu
    Central Laboratory, Shanghai Clinical Center, Chinese Academy of Sciences/Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai 200031, China.
  • Jianyong Shou
    EnnovaBio Pharmaceuticals, Shanghai 201203, China; Ennovabio (ZheJiang) Pharmaceuticals, Shaoxing, Zhejiang 312366, China. Electronic address: jianyong.shou@ennovabio.com.